Nanobiotix (NBTX) Current Deferred Revenue (2021 - 2025)

Nanobiotix's Current Deferred Revenue history runs 5 years deep, the most recent figure standing at $42.1 million for Q4 2025.

• On a quarterly basis, Current Deferred Revenue rose 117.86% year-over-year to $42.1 million in Q4 2025; TTM through Dec 2025 was $42.1 million, a 117.86% increase from a year earlier, with the FY2025 full-year figure at $40.9 million, up 111.46% from the prior year.
• Current Deferred Revenue improved to $42.1 million in Q4 2025 per NBTX's latest filing, from $40.9 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $42.1 million in Q4 2025 and bottomed at $16.9 million in Q4 2022.
• The 5-year median for Current Deferred Revenue is $19.4 million (2023), against an average of $24.0 million.
• Across the five-year window, Current Deferred Revenue slipped 10.72% in 2022 and soared 117.86% in 2025, its largest moves.
• Year by year, Current Deferred Revenue stood at $18.9 million in 2021, then decreased by 10.72% to $16.9 million in 2022, then grew by 15.56% to $19.5 million in 2023, then fell by 0.68% to $19.3 million in 2024, then surged by 117.86% to $42.1 million in 2025.
• Per Business Quant, the three latest NBTX Current Deferred Revenue figures stand at $42.1 million (Q4 2025), $40.9 million (Q2 2025), and $19.3 million (Q4 2024).